UPDATE: IBM (IBM) Estiamtes, PT Lowered to $112 at UBS; 'Not Immune to Macro, FX, Slowing IT'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 2/3/2023
- Wall Street ends down after stunning jobs growth raises Fed questions
- Elon Musk wins 'funding secured' trial
- U.S. nonfarm payroll growth blows past forecasts in January, up 517k
- Analysts defend Apple (AAPL) as earnings miss drags shares lower
- Amazon (AMZN) drops after earnings, analysts worried about AWS uncertainty
- Ford Motor (F) Declares $0.65 Special Dividend; 4.5% Yield
- Tenax Therapeutics (TENX) Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in PH-HFpEF
- Heart Test Laboratories (HSCS) Announces Further Internationalization of its Patent Portfolio
- Genius Group (GNS) Announces $10 Per Share Blockchain-based Digital Discount Coupon (NFT) Per Share
- Bill.com (BILL) Announces $300M Share Buyback
- Apple, Amazon, Alphabet, Ford all fall in premarket
- After-hours movers: Apple, Amazon, and Google all fall as results disappoint
- Meta leaps in premarket, pulling Amazon, Alphabet higher; Estee Lauder falls
- After-hours movers: Meta surges on better results, lifts other FAANG stocks
- Midday movers: Peloton Interactive, Electronic Arts, Match Group and more
IBM (IBM) Not Immune to Macro Headwinds- UBS
September 28, 2022 2:05 PM EDTUBS cut IBM's price target to $112 from $118 on Wednesday, maintaining a Sell rating on the stock, stating the company is not immune to macro.
Analyst David Vogt also lowered estimates as they believe consulting revenue growth is likely to slow faster than expected, IBM is facing incremental FX headwinds, and margins... More
